<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312232</url>
  </required_header>
  <id_info>
    <org_study_id>3112002</org_study_id>
    <nct_id>NCT02312232</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study in Healthy Males</brief_title>
  <acronym>NOCOF</acronym>
  <official_title>Pharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics of levodopa, carbidopa,
      3-OMD and ODM-104 after repeated doses of 3 levodopa formulations given in combination with
      carbidopa and ODM-104.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (Cmax) of levodopa</measure>
    <time_frame>24 hours</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax) of carbidopa, 3-OMD and ODM-104</measure>
    <time_frame>24 hours</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Levodopa formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levodopa formulation A together with ODM-104 100 mg and carbidopa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levodopa formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>levodopa formulation B together with ODM-104 100 mg and carbidopa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levodopa formulation C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>levodopa formulation C together with ODM-104 100 mg and carbidopa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinemet IR 100/25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinemet IR 100/25 mg together with ODM-104 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Half Sinemet CR 100/25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half Sinemet CR 100/25 mg together with ODM-104 100 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa, carbidopa, ODM-104</intervention_name>
    <arm_group_label>Levodopa formulation A</arm_group_label>
    <arm_group_label>levodopa formulation B</arm_group_label>
    <arm_group_label>levodopa formulation C</arm_group_label>
    <arm_group_label>Sinemet IR 100/25 mg</arm_group_label>
    <arm_group_label>Half Sinemet CR 100/25 mg</arm_group_label>
    <other_name>Sinemet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent (IC) obtained.

          -  Good general health ascertained by detailed medical history and physical examinations.

          -  Finnish speaking males 18-65 years of age (inclusive).

          -  Normal weight defined as a body mass index (BMI) &gt; 19 and &lt; 32 kg/m2 (BMI =
             weight/height2).

          -  Weight at least 60 kg.

          -  Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or
             other intestinal problems).

          -  Participants with female partners of child-bearing potential must adhere to a proper
             form of contraception (hormonal contraception or intrauterine device on female
             partner, and an additional barrier method used at least by one of the partners) from
             the first study treatment administration until 3 months after the end-of-study visit.

        Exclusion Criteria:

          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,
             gastrointestinal, pulmonary, metabolic-endocrine, malignancy, neurological or
             psychiatric disease within the previous 2 years.

          -  Inherited or family history (parents, siblings) of clinically significant cardiac
             conduction disease.

          -  Current/history of inflammatory bowel disease (IBDs): Colitis ulcerosa and Crohn's
             disease, celiac disease. Acute duodenal or gastric ulcer or gastritis, esophagitis,
             colon polyps or anal fissure.

          -  Any condition requiring regular concomitant treatment (including vitamins and herbal
             products) or likely to need any concomitant treatment during the study. As an
             exception, paracetamol for occasional pain is allowed.

          -  Intake of any medication that could affect the outcome of the study.

          -  Any clinically significant abnormal laboratory value or physical finding (including
             ECG and vital signs) that in the opinion of the investigator may interfere with the
             interpretation of study results or constitute a health risk for the subject if he
             takes part in the study.

          -  Known hypersensitivity to the active substances or the excipients of the drugs.

          -  History of vasovagal collapses or vagal reactions with unexplained reason within 2
             years or a tendency for vasovagal reactions during blood sampling.

          -  History of sleep apnea.

          -  Heart rate (HR) &lt; 40 bpm or &gt; 90 bpm after 10 minutes in supine position at the
             screening visit and predose.

          -  At the screening visit:

        systolic blood pressure (BP) &lt; 90 mmHg or &gt; 150 mmHg after 10 minutes in supine position
        diastolic BP &lt; 50 mmHg or &gt; 90 mmHg after 10 minutes in supine position

          -  Abnormal 24-hour Holter findings of clinical relevance according to cardiologistÂ´s
             assessment at the screening visit.

          -  History of anaphylactic/anaphylactoid reactions.

          -  History of seizures excluding febrile seizures during the first 6 years of life.

          -  Strong tendency to motion sickness.

          -  Recent or current (suspected) drug abuse.

          -  Recent or current alcohol abuse; regular drinking of more than 21 units per week (1
             unit = 4 cl spirits or equivalent).

          -  Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day
             and/or inability to refrain from the use of nicotine containing products during the
             study (from the screening visit to the end-of-study visit).

          -  Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability
             to refrain from the use of caffeine containing beverages during the treatment periods
             until 24 hours after study treatment administration.

          -  Blood donation or loss of significant amount of blood within 90 days prior to the
             first study treatment administration.

          -  Administration of another investigational drug within 90 days prior to the first study
             treatment administration.

          -  Unsuitable veins for repeated venipuncture or for cannulation.

          -  Predictable poor compliance or inability to communicate well with the study centre
             personnel.

          -  Inability to participate in all treatment periods.

          -  Participation in a clinical drug study during or within 3 months prior to the first
             study treatment administration.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mika Scheinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRST Turku</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRST</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>February 17, 2015</last_update_submitted>
  <last_update_submitted_qc>February 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

